#solar energy #United Kingdom #Piramal Pharma #Morpeth #Morpeth UK

Piramal Pharma Solutions Advances Sustainability Efforts with New Solar Power Plant

Piramal Pharma Solutions (PPS), a prominent player in the global Contract Development and Manufacturing Organization (CDMO) sector, is making significant strides in its sustainability initiatives with the installation of a new ground-mounted solar power plant at its facility in Morpeth, UK. This plant, with a capacity of 4.3 MWp, marks a substantial investment in renewable energy, aligning with PPS's goals to reduce greenhouse gas emissions significantly.

Key Details of the Solar Plant

Once operational, the solar installation is expected to generate approximately 3,950 MWh of renewable electricity annually, which will account for around 22% of the Morpeth facility's total electricity requirements. The expansive project will feature around 6,200 solar panels spread across an area of 16 acres, producing enough energy to power nearly 1,460 homes in the UK each year.

This venture is being realized under a Power Purchase Agreement (PPA) with Alight UK BTM1 Limited, a leading independent power producer and solar developer. The collaboration aims to facilitate a sustainable and cost-effective solution for onsite energy generation, pivotal for the long-term environmental strategy of Piramal Pharma Ltd.

Positive Environmental Impact

The addition of this solar power plant is projected to help the Morpeth site avoid emitting approximately 20,000 tons of carbon dioxide equivalent (tCO₂e) over the next 25 years. This commitment is a significant part of Piramal Pharma's decarbonization goals, which includes a target of reducing Scope 1 and Scope 2 greenhouse gas emissions by 42% by the fiscal year 2030.

Frank Bugg, Senior Vice President of UK and Europe Operations at PPS, emphasized the company's dedication to integrating sustainability into its operational decisions. He stated, "We are excited to advance our commitment to decarbonization and renewable energy with our partner Alight, bringing new value to our customers and shareholders worldwide."

The push for renewable energy reflects broader trends in the business landscape, where companies are increasingly searching for ways to enhance energy resilience, lower emissions, and manage energy costs effectively. Rob Stait, Managing Director at Alight, mentioned how this initiative exemplifies the potential of onsite solar projects to achieve these goals simultaneously.

Future Operations

The operational phase of the solar plant is expected to begin in the first quarter of 2027. This progression illustrates a crucial shift towards sustainability within the pharmaceutical manufacturing sector, showcasing how companies like Piramal Pharmapatent their leadership in adopting eco-friendly practices.

As global attention turns towards sustainable practices, initiatives like this not only demonstrate compliance with regulatory frameworks but also represent a proactive approach to corporate social responsibility. By investing in renewable energy, Piramal Pharma Solutions is not only addressing its own energy needs but also contributing positively to the environment and positioning itself at the forefront of pharmaceutical sustainability efforts.

About Piramal Pharma Solutions

Piramal Pharma Solutions offers comprehensive development and manufacturing solutions throughout the entire drug life cycle, leveraging a globally integrated network of facilities across North America, Europe, and Asia. With a diverse range of services that include drug discovery, clinical trial supplies, and commercial supply of APIs, PPS is dedicated to innovation and sustainable practices.

For more details about their initiatives and services, you can visit their official website or follow them on social media.